



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/239865/>

Version: Published Version

Article:

Katagira, W., Orme, M.W., Kasiita, R. et al. (2026) Clinical and cost-effectiveness of pulmonary rehabilitation for people with post-tuberculosis lung disease in Uganda: a randomised controlled trial. CHEST. ISSN: 0012-3692

<https://doi.org/10.1016/j.chest.2025.12.057>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Clinical Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation for People in Uganda With Post-TB Lung Disease

A Randomized Controlled Trial

Winceslaus Katagira; Mark W. Orme; Richard Kasiita; Jesse A. Matheson; Matthew Richardson; Andy Barton;

Jalia Nanyonga; Michael C. Steiner; Bruce Kirenga; and Sally J. Singh

BACKGROUND: Post-TB lung disease (PTLD) causes significant disability in survivors of TB. Pulmonary rehabilitation (PR) may offer effective disease management but lacks high-quality evidence in this underrepresented population.

RESEARCH QUESTION: Compared with usual care, does a 6-week PR program improve exercise capacity and health-related quality of life (HRQoL) cost-effectively in adults living with post-TB lung disease?

STUDY DESIGN AND METHODS: We conducted a single-center randomized controlled trial with blinded outcome assessments, comparing PR vs usual care (UC) for adults in Kampala, Uganda with PTLD. Participants were randomized (1:1) to receive either PR or UC, with assessments at 6 weeks postintervention. The primary outcome was change in exercise capacity measured by the Incremental Shuttle Walk Test. Secondary outcomes included HRQoL, respiratory symptoms, psychological well-being, and cost-benefit analysis. A generalized linear mixed model was used for the primary efficacy analysis (intention-to-treat) and a difference-in-differences analysis for secondary outcomes (modified intention-to-treat).

RESULTS: Between November 2020 and September 2022, 178 adults with PTLD were assessed for eligibility and 114 were randomized (mean age \pm SD, 43.3 ± 15.2 years; 65 [57%] were male). The postintervention improvement in mean Incremental Shuttle Walk Test in the PR group was significantly greater than in the UC group, by 54.36 m (95% CI, 17.22-91.51 m; $P = .004$). We also observed significant improvements in HRQoL in PR compared with UC: COPD Assessment Test score, -3.6 (95% CI, -6.7 to -0.39 ; $P = .015$); and Clinical COPD Questionnaire total, -0.37 (95% CI, -0.68 to -0.06 ; $P = .004$). The EuroQol Visual Analog Scale and quality-adjusted life-years (QALYs) marginally improved in the PR group vs the UC group: 3.98 (95% CI, -2.05 to 10.02 ; $P = .191$) and 0.02 (95% CI, -0.02 to 0.05 ; $P = .334$), respectively. The average cost of PR was \$6,468/QALY gained, equating to \$20,000/QALY gained after adjusting for purchasing power (below the National Institute for Health and Care Excellence cost-effectiveness threshold).

INTERPRETATION: In adults with PTLD, a 6-week PR program elicited clinically and statistically significant improvements in exercise capacity and HRQoL compared with UC, and was cost-effective.

CLINICAL TRIAL REGISTRATION: ISRCTN Clinical Trial Registry; No.: ISRCTN18256843; URL: isrctn.com CHEST 2026; ■(■):■-■

KEY WORDS: Africa; chronic respiratory disease; education; exercise; nondrug treatment; post-TB lung disease; pulmonary rehabilitation; quality of life; TB

Take-Home Points

Research Question: Compared with usual care, does a 6-week pulmonary rehabilitation program improve exercise capacity and health-related quality of life cost-effectively in adults living with post-tuberculosis lung disease?

Results: The 6-week pulmonary rehabilitation program demonstrated statistically significant and clinically meaningful improvements in exercise capacity and health-related quality of life compared with usual care, and was cost-effective.

Interpretation: In people with disability associated with post-tuberculosis lung disease, pulmonary rehabilitation improves exercise capacity and health-related quality of life, and provides good value for money.

Despite TB being the leading cause of infectious disease deaths, national TB programs have made progress, with 155 million survivors by 2020, including 25.7 million in Africa.¹ Many survivors of pulmonary TB continue to experience chronic respiratory symptoms after microbiologic cure, partly attributable to the permanent lung parenchymal damage caused by *Mycobacterium tuberculosis*.² Pulmonary TB can cause lasting damage to the airways, lung parenchyma, pleura, or pulmonary vasculature,^{3,4} leading to persistent respiratory symptoms, a condition known as post-TB lung disease (PTLD),⁵ a type of chronic respiratory disease (CRD).⁶

Adults with PTLD develop secondary systemic impairments including skeletal muscle dysfunction and wasting, systemic inflammation, and oxidative stress.⁶⁻⁸ The systemic impairments are often compounded by physical inactivity, leading to significant impairment in daily functioning, inability to work, and reduced health-related quality of life (HRQoL).^{9,10} Considering that most survivors of pulmonary TB are young people, the

ABBREVIATIONS: CAT = COPD Assessment Test; CCQ = Clinical COPD Questionnaire; CRD = chronic respiratory disease; DiD = difference-in-differences analysis; EQ-5D-5L = European Quality of Life 5-Dimensions 5-Level; EQ-VAS = EuroQol Visual Analog Scale; GLMM = generalized linear mixed model; HADS = Hospital Anxiety and Depression Scale; HRQoL = health-related quality of life; ICER = incremental cost-effectiveness ratio; ISWT = Incremental Shuttle Walk Test; ITT = intention to treat; MCID = minimal clinically important difference; mITT = modified intention to treat; MRC = Medical Research Council; PR = pulmonary rehabilitation; PTLD = post-TB lung disease; QALY = quality-adjusted life-years; RCT = randomized controlled trial; UC = usual care

AFFILIATIONS: From the Makerere University Lung Institute (W. K. and J. N.), Kampala, Uganda; the Department of Respiratory Sciences (M. W. O., M. R., A. B., M. C. S., and S. J. S.), University of Leicester;

economic impact on this group can be substantial.¹ At present, there are no known effective medicines for PTLD. Pulmonary rehabilitation (PR) is a low-cost, high-impact nonpharmacologic intervention that reverses the disability from CRDs such as COPD, and is backed by strong evidence in high-income countries.^{11,12} However, its efficacy in PTLD-associated disability lacks strong evidence.

Consensus statements on the management of PTLD recommend PR, but, to date, this is not backed by high-quality evidence.¹³ The World Health Organization (WHO) Rehabilitation 2030 initiative calls for robust evidence on rehabilitation for many chronic diseases.¹⁴ However, data on the clinical efficacy and cost-effectiveness of interventions that reverse PTLD-associated disability remain limited. In a systematic review of interventions to prevent post-TB sequelae, only 6 of 25 studies addressed pulmonary sequelae,¹⁵ and the PR studies in low-resource, high-TB burden settings were underpowered.¹⁶

Accordingly, we conducted an adequately powered randomized controlled trial (RCT) with blinded outcome measures to compare PR with usual care in people with PTLD, with the primary outcome as exercise capacity.

Study Design and Methods

A single-center RCT with blinded outcome assessments comparing PR vs usual care for adults living in Kampala, Uganda with PTLD was conducted.

Consenting participants were randomized 1:1 to receive either PR or usual care (waiting list), using a secure, password-protected web-based system,¹⁷ which generated a random allocation sequence. An independent team member, using a completed checklist, conducted randomization and relayed study ID and allocation to

the Centre for Exercise and Rehabilitation Science (CERS) (M. W. O., M. C. S., and S. J. S.), NIHR Leicester Biomedical Research Centre—Respiratory, University Hospitals of Leicester NHS Trust, Leicester; the Department of Physiotherapy (R. K.), Mulago Hospital, Kampala, Uganda; and the Department of Economics (J. A. M.), University of Sheffield, Sheffield, England.

CORRESPONDENCE TO: Wincelous Katagira, MD; email: wincegira@gmail.com Q5 Q14

Copyright © 2026 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

DOI: <https://doi.org/10.1016/j.chest.2025.12.057>

the data collection and intervention teams, which then informed the participants.

As PR precludes blinding, participants were requested not to disclose their allocation. Blinded staff conducted outcome assessments, prioritizing the Incremental Shuttle Walk Test (ISWT) to minimize unblinding risk, and followed standardized procedures requiring documentation of any suspected unblinding.

The study was conducted at the PR center of the Lung Institute Clinic, an academic outpatient facility with a skilled PR team of health care professionals delivering PR to patients with PTLD and COPD for nearly 8 years before the study. Adults with PTLD were referred from TB and HIV/TB care centers. PTLD was defined as completion of treatment for microbiologically confirmed pulmonary TB, with persistent respiratory symptoms at enrollment, and radiologic evidence of lung parenchymal damage consistent with TB on frontal chest radiography, confirmed by a radiologist.

Eligible participants were adults (≥ 18 years) with PTLD, able to provide written informed consent, with a documented history of smear-positive pulmonary TB (≥ 6 months before enrollment), a negative result for the Xpert MTB/RIF (*Mycobacterium tuberculosis* [MTB] and rifampicin [RIF] resistance) assay (Cepheid) at enrollment, and Medical Research Council (MRC) dyspnea grade ≥ 2 .

Participants were excluded if they had comorbidities precluding exercise (eg, unstable cardiovascular disease) or any condition that, in the judgment of the investigator, made participation unsafe.

Participants in the intervention arm received PR in addition to the usual care described below. PR comprised a 6-week program, delivered in groups of 6 to 10 participants, with twice-weekly, 2-hour face-to-face sessions. The exercise regimen was individualized on the basis of baseline ISWT performance and progressively adjusted during the program according to health status and exercise response. Group warm-up and cool-down sessions were provided before and after exercises. Participants then completed 6 exercise stations: 2 for endurance (load-adjustable stationary cycling and walking) and 4 for muscle strengthening (pull-ups, biceps curls, sit-to-stand, and step-ups). Each station involved 3 sets of 8 to 12 repetitions. Participants were also encouraged to continue both endurance and strength exercises at home. Each PR session began with a bespoke group education program

covering a range of topics as described in the protocol.¹⁸ Adherence to the intervention was defined as attending $\geq 75\%$ of PR sessions (9 of 12 face-to-face sessions), and attendance at the 6-week follow-up assessment.

In the absence of PTLD-specific management guidelines, usual care comprised inhalational therapies for spirometry-confirmed airway diseases and verbal advice on smoking cessation and biomass smoke avoidance. All participants underwent frontal chest radiograph and spirometry conducted according to the American Thoracic Society/European Respiratory Society guidelines and the National Health and Nutrition Examination Survey III (NHANES III) reference values.¹⁹ Participants with spirometry-confirmed medical syndromes were managed according to Global Initiative for Asthma (GINA)²⁰ and Global Initiative for Obstructive Lung Disease (GOLD)²¹ recommendations. Before enrollment, participants with medical syndromes were treated until clinically stable to participate in trial activities. All participants were encouraged to stay physically active while at home. Usual care participants were offered PR after the 12-week follow-up visit.

The primary outcome was change in the mean ISWT walking distance, with a minimal clinically important difference (MCID) of 35 m.²² The ISWT is an externally paced field test widely used to assess maximal exercise capacity in people with CRD. Exercise prescription is based on data from the ISWT and corresponds to 80% of the maximal performance of the individual on the test.²³

The secondary outcomes, based on PR minimum measures for low- and middle-income countries,²⁴ included respiratory health (Clinical COPD Questionnaire [CCQ] and COPD Assessment Test [CAT] scores), mental health (Hospital Anxiety and Depression Scale [HADS] and Patient Health Questionnaire-9 [PHQ-9]), and functional status (Endurance Incremental Shuttle Walk Test [ESWT], 5-repetition sit-to-stand [FTSTS], and MRC dyspnea scale). Overall health was assessed with the EuroQol Visual Analog Scale (EQ-VAS). All secondary outcomes are responsive to PR in COPD populations with the following MCIDs, respectively: CCQ (0.4),²⁵ CAT (2 points),²⁶ HADS (2 points),^{27,28} PHQ-9 (5 points),²⁹ ESWT (between 174 and 279 s),³⁰ FTSTS (1.7 s),³¹ MRC dyspnea scale (1 point),^{32,33} and EQ-VAS (8 points).³⁴

HRQoL was assessed with the EuroQol (EQ-5D-5L) questionnaire. Using country-specific value sets,

331 responses to the EQ-5D-5L questionnaire were mapped
 332 to indices reflecting quality-adjusted life-years
 333 (QALYs)^{35,36} for each observation in the data. As the
 334 value sets did not include index values specific to
 335 Uganda, we calculated values from all available coun-
 336 tries and report the most conservative estimates, based
 337 on Zimbabwe index values, in the primary analysis.
 338 The change in QALYs from baseline to the 6-week
 339 follow-up was then compared between the PR and usual
 340 care groups.

342 The incremental cost-effectiveness ratio (ICER) was
 343 calculated as the cost per patient divided by the change
 344 in QALYs for the PR, relative to the usual care arm. The
 345 calculated ICER was then compared with the cost-
 346 effectiveness threshold proposed by the National Insti-
 347 tute for Health and Care Excellence (NICE) in the
 348 United Kingdom. NICE uses a threshold of £20,000 to
 349 £30,000 (\$26,000–\$39,000/QALY gained)³⁷ to deter-
 350 mine whether a health care intervention provides
 351 good value for money, with interventions below this
 352 threshold generally considered cost-effective. Because
 353 an equivalent threshold does not currently exist for
 354 Uganda, the resulting ICER was adjusted for the pur-
 355 chasing power of Uganda.
 356
 357

358 Safety was assessed for all randomized participants. In
 359 the PR arm, adverse events were considered related if
 360 they occurred during exercise and had no other alterna-
 361 tive cause.
 362

363 The study was powered to detect a 35-m difference in
 364 the distance walked on the ISWT measured at baseline
 365 and after completion of 6 weeks of PR.²² Assuming that
 366 ISWT follows an approximately normal distribution, a
 367 power calculation based on a paired *t*-test was per-
 368 formed. On the basis of a trial sample size of 40 partic-
 369 ipants in each of the intervention and usual care groups,
 370 a 2-sided 5% significance level and a statistical power of
 371 80%, the clinically important change in ISWT of 35 m
 372 would also be statistically significant. Our feasibility
 373 study was used to obtain an estimate of the pooled SD
 374 for the power calculation. Conservatively assuming up
 375 to 30% loss to follow-up at 6 weeks, 114 participants
 376 were required to be recruited and randomized (1:1) to
 377 each arm (57 participants in each group).
 378
 379

380 All randomized participants were included in the
 381 intention-to-treat (ITT) analysis for the primary
 382 outcome. Secondary outcomes were analyzed using
 383 the modified intention-to-treat (mITT) population,
 384 defined as those with ISWT data at baseline and
 385 6-week follow-up.

The primary outcome (change in the mean ISWT dis-
 tance) was analyzed with a generalized linear mixed
 model (GLMM), with time point and treatment group
 as fixed effects. To improve precision, baseline vari-
 ables that differed by chance between the PR and
 usual care arms ($P \leq .05$) were assessed for multicol-
 linearity. The final adjusted model retained CAT
 score, post-bronchodilator FEV₁/FVC ratio, and hos-
 pitalizations in the preceding 12 months. A mixed-
 effects GLMM with cluster-specific random intercepts
 was fitted by maximum likelihood, justified by a high
 intraclass correlation coefficient (0.72). The goodness-
 of-fit indices and residual diagnostics indicated good
 model performance without overdispersion. The re-
 sults are reported as mean differences with the corre-
 sponding 2-sided 95% CI and *P* value < .05
 considered statistically significant. The detailed
 GLMM methodology is provided in the online
 supplement.

Secondary outcomes were analyzed in the mITT popu-
 lation using a difference-in-differences (DiD) analysis,
 adjusting for the multiplicity of null hypotheses incor-
 porating a treatment × time interaction. Where rele-
 vant, adjustments for multiple comparisons were
 made using the “mhtexp” package for Stata,³⁸ which
 adjusts *P* values and SEs for correlated outcomes, supple-
 mented by Bonferroni and Holm corrections. SEs were
 derived from 10,000-iteration bootstraps. Secondary
 outcomes were additionally evaluated as change scores,
 using linear regression with cluster-robust SEs. Model
 diagnostics including histograms, Q-Q plots, and
 residual-fitted plots showed no major assumption
 violations.

The full DiD methodology is available in the online
 article. Continuous variables are presented as mean
 and SD or as median and interquartile ranges, and cat-
 egorical data are presented as frequencies and percent-
 ages. Normality was assessed to guide use of parametric
 and nonparametric tests. Group comparisons were done
 with χ^2 and Fisher exact tests for categorical data, and *t*-
 test (normally distributed) and Mann-Whitney *U* test
 (nonnormally distributed) for continuous data. All ana-
 lyses were conducted with STATA version 17 software
 (2021; StataCorp).

The study received ethics approval locally and interna-
 tionally (MHREC-1478, SS-5105, and University of
 Leicester, United Kingdom research ethics committee
 [Ref. No. 22349]), and all participants provided written
 informed consent before inclusion in the study, in

386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440

accordance with the Declaration of Helsinki. We followed the CONSORT (Consolidated Standards of Reporting Trials) 2010 reporting guidelines and the

CONSORT extension for nonpharmacologic interventions. The trial was prospectively registered at ISRCTN.³⁹

Results

This RCT was conducted from November 20, 2020, to September 30, 2022. Enrollment began on November 20, 2020, but was paused on June 6, 2021, during the second wave of the COVID-19 pandemic due to government restrictions to limit infection spread. The pause increased loss to follow-up because in-person assessments were required per protocol. No participant withdrew, but 22 (19.3%) were lost to follow-up due to COVID-19-related transport disruptions.

Of 178 adults with prior PTB treatment screened for study eligibility, 114 (64%) consented and were randomized 1:1 to receive either PR or usual care (Fig 1). Twenty-two participants (9 in PR arm and 13 in usual care arm) missed the 6-week follow-up ISWT.

The baseline demographic and clinical characteristics between the study groups were largely similar (Table 1):

mean \pm SD age, 43.3 ± 15.2 years; predominantly male ($n = 65$ [57%]). All 114 participants were included in the ITT analysis at 6 weeks follow-up. The mITT analysis included 92 participants (81%) who completed both baseline and 6-week ISWT (48 in PR, 44 in UC). In the PR arm, 41 attended $\geq 75\%$ of face-to-face PR sessions. Twenty-two (19.3%) were lost to follow-up.

The absolute change in ISWT from baseline to 6 weeks was $+49.3$ m in the PR group and -1.4 m in the UC group, yielding a between-group difference in mean change of 50.7 m. After adjusting for baseline chance imbalances, the GLMM analysis showed that at 6 weeks, the PR group achieved a significantly greater mean ISWT distance and exceeded that in the UC group by 54.36 m (95% CI, 17.22 - 91.51 m; $P = .004$) (Fig 2). Notably, the mean ISWT improvement in PR exceeded the MCID of 35 m.




Figure 1 – Consolidated Standards of Reporting Trials (CONSORT) diagram of participants in the pulmonary rehabilitation trial for post-tuberculosis lung disease.

TABLE 1] Baseline Characteristics of Participants With Post-TB Lung Disease for the PR Trial, Overall and by Group Allocation

Characteristic	Overall (N = 114)	Pulmonary Rehabilitation (n = 57)	Usual Care (n = 57)
Sex			
Female	49 (43)	23 (40)	26 (46)
Male	65 (57)	34 (60)	31 (54)
Age, y ^a	43.3 (15.2)	45.8 (16.0)	40.8 (14.0)
Age when leaving school, y ^a	18.2 (7.6)	18.1 (9.3)	18.3 (5.3)
Time since completing TB treatment, mo	65.4 (70.5)	66.9 (68.8)	63.8 (72.7)
History of smoking			
Active tobacco smoking	1 (0.9)	1 (1.8)	0 (0)
Previous tobacco smoking	30 (26.3)	16 (28.0)	14 (24.6)
Never smoked tobacco	83 (72.8)	40 (70.2)	43 (75.4)
History of biomass exposure			
Current	43 (37.7)	24 (45.3)	26 (50)
Former	50 (43.9)	6 (11.3)	6 (11.5)
Never	12 (10.5)	23 (43.4)	20 (38.5)
HIV positive	30 (28.9)	16 (31.4)	14 (26.4)
HIV positive while receiving ART	30 (100)	16 (100)	14 (100)
ART duration, mo ^a	119.6 (95.2)	122.9 (108.5)	115.8 (81.3)
BMI, kg/m ^{2a}	20.4 (4.8)	20.5 (5.0)	20.3 (4.6)
Employment status			
Employed in paid work	32 (28.0)	11 (19.3)	21 (36.8)
Self-employed	28 (24.6)	13 (22.8)	15 (26.3)
In unpaid work	2 (1.8)	1 (1.8)	1 (1.8)
Not working	52 (45.6)	32 (56.1)	20 (35.1)
Highest education			
No formal education	2 (1.8)	2 (3.9)	0 (0)
Incomplete primary	21 (18.4)	10 (19.2)	11 (21.6)
Complete primary	14 (12.3)	9 (17.3)	5 (9.8)
Incomplete secondary	37 (32.5)	19 (36.5)	18 (35.3)
Complete secondary	10 (8.8)	4 (7.4)	6 (11.8)
Tertiary	19 (16.7)	8 (15.4)	11 (21.6)
Exercise capacity			
MRC dyspnea grade			
Grade 2	66 (58)	28 (49)	38 (67)
Grade 3	41 (36)	25 (44)	16 (28)
Grade 4	7 (6)	4 (7)	3 (5)
Sit-to-stand 5-s repetitions ^a	9.7 (2.7)	9.9 (3.0)	9.4 (2.4)
Baseline ISWT distance, m ^a	392.6 (131.6)	376.5 (132.0)	408.8 (130)
Endurance Shuttle Walking Test, s ^a	581.7 (362.1)	570.4 (342.1)	592.9 (384.4)
Spirometry			
TB-associated obstruction	29 (25.4)	16 (28.1)	13 (22.8)
Restriction	26 (22.8)	14 (24.6)	12 (21.0)
Reversibility	20 (17.6)	13 (22.8)	7 (12.3)
Normal spirometry	34 (29.8)	12 (21.0)	22 (38.6)

(Continued)

TABLE 1] (Continued)

Characteristic	Overall (N = 114)	Pulmonary Rehabilitation (n = 57)	Usual Care (n = 57)
Failed spirometry	5 (4.4)	2 (3.5)	3 (5.3)
Pre-BD FVC % predicted ^a	74.3 (22.5)	69.2 (21.6)	79.5 (22.3)
Pre-BD FEV ₁ % predicted ^a	63.8 (25.1)	57.1 (22.3)	70.5 (26.1)
Respiratory health and HRQoL			
CAT score ^a	17.5 (8.13)	19.7 (7.66)	15.3 (8.06)
PHQ-9 total score ^a	2.01 (3.22)	2.26 (3.2)	1.75 (3.10)
CCQ total score ^a	2.08 (0.89)	2.25 (0.84)	1.91 (0.89)
CCQ symptom score ^a	2.66 (1.19)	2.96 (1.14)	2.37 (1.17)
CCQ mental state score ^a	1.26 (1.37)	1.30 (1.41)	1.22 (1.35)
CCQ functional state score ^a	1.95 (0.90)	2.10 (0.87)	1.80 (0.91)
HADS Depression ^a	1.85 (3.58)	1.81 (3.35)	1.89 (3.83)
HADS Anxiety ^a	1.42 (2.97)	1.19 (2.45)	1.65 (3.43)
EuroQoL-VAS ^a	67.1 (16.2)	64.4 (15.6)	69.7 (16.5)
Comorbidities			
Hypertension	8 (7)	6 (10.5)	2 (3.5)
Cardiac disease	1 (0.9)	1 (1.8)	0 (0)
Arthritis	2 (1.8)	2 (3.5)	0 (0)
Medicines			
LAMA	4 (3.5)	3 (5.3)	1 (1.8)
ICS/LABA	25 (21.9)	16 (28.1)	9 (15.8)
ICS	2 (1.8)	2 (3.5)	0 (0)
Systemic steroids	4 (3.5)	3 (5.3)	1 (1.8)
Cough syrups	7 (6.1)	4 (7.0)	3 (5.3)
Antibiotics	11 (9.7)	6 (10.5)	5 (8.8)
Hospitalizations in the past 12 mo ^a	0.12 (0.32)	0.19 (0.39)	0.05 (0.22)
Nutritional status			
Mid-upper arm circumference ^a	25.7 (22.3)	23.8 (5.3)	27.6 (31.1)
Thigh circumference ^a	45.8 (9.3)	45.8 (8.1)	45.8 (10.4)

Categorical variables are presented as No. (%), unless indicated otherwise. ART = antiretroviral therapy; BD = bronchodilator; CAT = COPD Assessment Test; CCQ = Clinical COPD Questionnaire; EuroQoL-VAS = Visual Analog Scale; HADS = Hospital Anxiety and Depression Scale; HRQoL = health-related quality of life; ICS = inhaled corticosteroid; ISWT = Incremental Shuttle Walk Test; LABA = long-acting β -agonist; LAMA = long-acting muscarinic agonist; MRC = Medical Research Council; PHQ-9 = Patient Health Questionnaire-9; PR = pulmonary rehabilitation.

^aValues represent mean (SD).

The DiD analysis performed on the mITT population for secondary outcomes at the 6-week follow-up (Table 2) showed statistically significant improvements in the PR arm vs usual care arm for the CAT score (−3.6 [95% CI, −6.7 to −0.39]; $P = .015$), CCQ total (−0.37 [95% CI, −0.68 to −0.06]; $P = .004$) and functional domain (−0.40 [95% CI, −0.71 to −0.09]; $P = .002$), as well as MRC dyspnea score (−0.28 [95% CI, −0.54 to −0.2]; $P = .030$). Participants in PR achieved an improvement exceeding the MCID of 2 points for CAT score and reached 0.4 points for CCQ score.

The DiD analysis of the EQ-VAS group means of the mITT population at 6-week follow-up was positive in

the PR arm but not statistically significant (3.98 [95% CI, −2.05 to +10.02]; $P = .191$). After mapping EQ-5D-5L survey responses, the DiD analysis of the resulting QALYs for the mITT population at the 6-week assessment was positive for the PR arm, but not statistically significant (0.02 [95% CI, −0.02 to +0.05]; $P = .334$).

The cost of running the PR program, excluding research expenses, amounted to \$6,850, which translates to \$114/participant. When evaluated on the basis of the average QALY gained from the PR in the mITT population, this results in a cost of \$6,468/QALY gained. After adjusting for the purchasing power of Uganda, the cost was




Figure 2 – Mean change in ISWT distance between baseline and 6-week follow-up, by group allocation with 95% CIs. ISWT = Incremental Shuttle Walk Test; PR = pulmonary rehabilitation.

\$20,000/QALY gained (GBP £15,400/QALY). However, because the estimated average QALY gained was not statistically significant, the cost-effectiveness should be interpreted with caution, although the results suggest potential value.

The DiD analysis, performed on the mITT population, showed that the improvements were maintained at the 12-week follow-up visit (e-Table 1).

Adverse events (e-Table 2) were reported in 18 (15.8%) trial participants (12 [21%] in the PR arm vs 6 [10.5%] in the usual care arm). The most common adverse event was exacerbation of post-TB airway syndromes (12 of 18; 67%). Two participants in the PR arm experienced severe adverse events requiring hospitalization, both unrelated to the study: 1 due to a road traffic accident post-PR, and another for severe exacerbation of post-TB airway syndrome.

Discussion

In this RCT of PR in PTLT, participants in the 6-week PR program showed statistically significant and clinically meaningful improvements in exercise capacity and HRQoL, and the intervention was cost-effective. Our study shows that it is possible to set up and deliver a clinical and cost-effective PR program for an underrepresented patient group in a resource-limited setting. This supports the goal of the WHO Rehabilitation 2030 initiative: to make rehabilitation

services accessible and affordable, particularly in low- and middle-income countries.¹⁴

Our findings are consistent with those from a pre-post study of PR in PTLT.⁴⁰ We observed a similar magnitude of improvement in the outcomes of interest, which are corroborated by findings from other observational and underpowered studies in this population.^{15,41-44}

Our adequately powered clinical trial makes an important contribution to the evidence of PR in the PTLT population. Participants with PTLT registered significant improvements in walking distance, above the group mean MCID of 35 m for a COPD population²² we had set for the trial. The change in walking distance observed in our trial was comparable to that seen in other CRDs.^{22,45,46} Importantly and interestingly, our study population was much younger and had fewer comorbidities compared with typical COPD cohorts attending PR in higher-income settings.⁴⁷ We had previously established the feasibility of delivering such an intervention to this younger population, and our observed dropout rate was comparable to other PR studies. Our demographic data reveal that many participants traveled significant distances, which in our country took a considerable amount of time. In addition to being younger, our population had a distinct comorbidity profile, with a notable proportion living with HIV. This is rare in high-income countries and

881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935

TABLE 2] Adjusted Changes in Study Outcomes From Baseline to 6 Weeks, by Group Allocation

	Pulmonary Rehabilitation Arm			Usual Care Arm			Difference in Difference (95% CI)	P Value (Adjusted)
	Baseline Mean (SD)	6 Weeks Mean (SD)	Difference in Means	Baseline Mean (SD)	6 Weeks Mean (SD)	Difference in Means		
Primary Outcome (Intention-to-Treat Population)								
Incremental Shuttle Walk Test, m ^a	381.7 (135.6)	431.0 (144.4)	49.3	415.0 (127.1)	413.6 (141.8)	-1.4	54.36 (17.22 to 91.51)	.004 ^a
Secondary Outcomes (Modified Intention-to-Treat Population)^b								
Endurance Shuttle Walk Test, s	596.1 (360.0)	572.0 (445.8)	-24.1	619.0 (404.8)	613.4 (397.0)	-5.6	-23.7 (-214.2 to 166.9)	.803
MRC dyspnea grade	2.54 (0.62)	1.91 (0.60)	-0.63	2.41 (0.62)	2.02 (0.86)	-0.39	-0.28 (-0.54 to -0.2)	.030
Sit-to-stand repetitions in 5 s	9.91 (3.0)	8.16 (2.3)	-1.75	9.46 (2.33)	8.95 (2.36)	-0.51	-0.67 (-1.65 to 0.32)	.178
CAT score	18.4 (7.9)	10.9 (6.9)	-7.5	14.9 (7.2)	11.2 (8.3)	-3.7	-3.6 (-6.7 to -0.39)	.015
CCQ total	2.12 (0.9)	1.38 (0.8)	-0.74	1.91 (0.84)	1.58 (0.8)	-0.33	-0.37 (-0.68 to -0.06)	.004
CCQ symptoms	2.71 (1.1)	2.01 (1.22)	-0.7	2.36 (1.1)	1.98 (1.2)	-0.38	-0.40 (-0.90 to 0.11)	.036
CCQ functional	1.96 (0.74)	1.34 (0.9)	-0.62	1.82 (0.9)	1.68 (1.0)	-0.14	-0.40 (-0.71 to -0.09)	.002
CCQ mental	1.27 (1.5)	0.19 (0.6)	-1.08	1.2 (1.3)	0.58 (1.1)	-0.62	-0.24 (-0.83 to 0.34)	.416
HADS depression	1.77 (3.1)	0.40 (1.5)	-1.37	2.15 (4.0)	1.0 (2.8)	-1.15	0.15 (-1.25 to 1.55)	.881
HADS anxiety	1.13 (2.2)	0.34 (1.3)	-0.79	1.84 (3.6)	0.91 (2.6)	-0.93	0.37 (-0.64 to 1.38)	.571
PHQ-9	2.34 (3.4)	0.50 (1.5)	-1.84	1.90 (3.3)	1.02 (2.5)	-0.88	-0.5 (-0.73 to 0.73)	.300
BMI, kg/m ²	20.2 (4.4)	21.2 (4.4)	1.0	20.5 (4.4)	20.9 (4.5)	0.4	0.003 (-0.65 to 0.65)	.993
EuroQol Visual Analog Scale	63.84 (16.1)	79.0 (15.8)	15.16	69.17 (16.7)	79.38 (16.1)	10.21	3.98 (-2.05 to 10.02)	.191

CAT = COPD Assessment Test; CCQ = Clinical COPD Questionnaire; GLMM = generalized linear mixed model; HADS = Hospital Anxiety and Depression Scale; ITT = intention to treat; MRC = Medical Research Council; PHQ-9 = Patient Health Questionnaire-9.

^aGLMM analysis of the ITT population.

^bAdjustments for multiple comparisons were made using the mhtexp package with *P* values and SEs adjusted for multiple hypotheses.

936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990

seldom reported in PR trials. However, this study was underpowered to assess the impact of HIV on PR for this group. Despite being younger, our cohort (mean age, 43.3 ± 15.2 years) had a baseline ISWT of 392.6 ± 131.6 m, comparable to UK COPD cohorts (483 ± 148 m; mean age, 69.4 ± 9.1 years),⁴⁸ underscoring the impact of PTLD on physical capacity. PR may significantly benefit young, economically active people with PTLD-associated disability.

An additional feature of this trial is the use of the ISWT, a reliable, objective, and more standardized measure of exercise capacity compared with other field walking tests²³ used in other studies of PR in the PTLD population, described in the systematic review by Alene and colleagues.¹⁵

Although the symptom burden, HRQoL, anxiety, and depression in our study were lower than in COPD populations,⁴⁹ PR in our PTLD population nonetheless yielded improvements in HRQoL, exercise capacity, and respiratory symptoms. Notably, although the CCQ total score did not reach the MCID, the functional domain did, highlighting the effect of PR on improving physical and social functioning, the key components of HRQoL, and suggesting that domain-specific measures may be more sensitive in capturing therapeutic benefits than aggregate scores. These findings align with the review by Alene and colleagues,¹⁵ which noted PR benefits, although with caution due to limited data. Anxiety and depression showed marginal improvement, likely due to low baseline levels.

Furthermore, we conducted a cost-benefit assessment, and after adjusting for the purchasing power of Uganda, our PR program was cost-effective in eliciting meaningful clinical improvements, providing a robust foundation of high-quality evidence to support policy change. Our PR program was below the NICE cost-effectiveness threshold of less than £20,000/QALY gained.⁵⁰ Tailored PR programs that address the specific needs of patients with PTLD play a crucial role in improving functional status and quality of life in this population. Providing low-cost PR to patients with PTLD, with no effective treatment options, therefore represents good value for money, considering the health gains achieved relative to the resources required to deliver the program. This could, therefore, impact policy decisions regarding the implementation and

provision of PR for the PTLD population, which is often a neglected and underrepresented group of young people in their economically productive years. The evidence from this study supports expanding PR across regions with high numbers of TB survivors and a rising burden of PTLD disability.

The findings from this study should be considered within the context of its limitations. Despite successful randomization, the modest sample size resulted in chance baseline imbalances between groups. These were, however, addressed in the GLMM to improve precision. We chose to consider the value of exercise-based PR in the post-TB treatment phase; however, there may be merit in exploring the value of PR alongside concurrent medical management of TB. In the absence of PTLD-specific outcome measures, we used instruments developed for COPD, which, although fundamentally sensitive, may be limited in capturing experiences and outcomes most relevant to this population, such as stigma. We acknowledge there is no established MCID in PTLD; however, our primary outcome measure was an objective, disease-agnostic measure of performance. In addition, we lacked a country-specific EQ-5D-5L value set for QALY calculation; however, we tested the sensitivity of our analysis by using available sets, all yielding cost/QALY estimates within the NICE threshold. Last, as a single-center RCT, generalizability of these findings may be limited, although they remain informative for similar settings.

Interpretation

In a young study population with disability associated with PTLD, our 6-week PR program improved exercise capacity in a clinically meaningful manner and was cost-effective.

Funding/Support

This research was funded by the NIHR (17/63/20) using UK aid from the UK government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK government. S. J. S. is a NIHR Senior Investigator.

Financial/Nonfinancial Disclosures

None declared.

1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100

Acknowledgments

Author contributions: All authors were involved in all the stages of manuscript development and participated fully in the review and editing of the manuscript, and were fully involved in decision-making to submit the manuscript for publication. W. K., B. K., S. J. S., M. W. O., and A. B. contributed to conceptualization, design of the study, and data acquisition. W. K., J. N., and R. K. contributed to data acquisition. W. K., J. A. M., A. B., M. W. O., and M. R. contributed to data acquisition and data analysis and interpretation. W. K., B. K., S. J. S., M. W. O., J. A. M., A. B., and M. R. contributed to data analysis and interpretation. W. K., J. A. M., M. W. O., A. B., and M. R. accessed and verified the underlying data reported in the manuscript.

Role of sponsor: The funder of this clinical trial did not participate in the design, data collection, analysis, interpretation, or report writing.

Disclaimer: The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.

Other contributions: The authors extend their heartfelt gratitude to everyone who contributed to the success of this clinical trial. They are especially thankful to the study participants for their time, dedication, and engagement throughout the trial. The sincere thanks of the authors also go to the collaborating institutions, project staff, and Centre for Exercise and Rehabilitation Science (CERS) for their invaluable guidance and expertise. The authors acknowledge the funding support from the UK National Institute for Health and Care Research (NIHR). To ensure open access, a Creative Commons Attribution license (CC BY) has been applied to any Author Accepted Manuscript version resulting from this submission.

Data sharing: The data collected for the trial, including individual deidentified participant data and a data dictionary defining each field in the set, will be made available. The study protocol and statistical analysis plan (SAP) are available online. The protocol citation is as stated above, and the SAP is uploaded to the ISRCTN database and can be accessed with the support of the investigator after stating the purpose, and types of analysis, and with a signed data access agreement.

Additional information: The e-Tables are available online under "Supplementary Data."

References

- Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. *Lancet Infect Dis*. 2021;21(7):984-992.
- Harries A, Ade S, Burney P, Hoa N, Schluger N, Castro J. Successfully treated but not fit for purpose: paying attention to chronic lung impairment after TB treatment. *Int J Tuberc Lung Dis*. 2016;20(8):1010-1014.
- Kim HY, Song K-S, Goo JM, Lee JS, Lee KS, Lim T-H. Thoracic sequelae and complications of tuberculosis. *Radiographics*. 2001;21(4):839-858.
- Menon B, Nima G, Dogra V, Jha S. Evaluation of the radiological sequelae after treatment completion in new cases of pulmonary, pleural, and mediastinal tuberculosis. *Lung India*. 2015;32(3):241-245.
- Allwood B, van der Zalm M, Amaral A, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. *Int J Tuberc Lung Dis*. 2020;24(8):820-828.
- Choi C-J, Choi W-S, Kim C-M, Lee S-Y, Kim K-S. Risk of sarcopenia and osteoporosis in male tuberculosis survivors: Korea National Health and Nutrition Examination Survey. *Sci Rep*. 2017;7(1):13127.
- Mohamad Zani RA, Ahmad Yusof H, Azizan NA, Hyder Ali IA, Ismail S, Mohd Shariff N. Sarcopenia and its influencing factors among adults with asthma, chronic obstructive pulmonary disease, and tuberculosis in Penang, Malaysia. *BMC Public Health*. 2025;25(1):1572.
- Shin M-K, Choi JY, Kim SY, et al. Association of protein consumption and energy intake on sarcopenia in tuberculosis survivors. *Thorax*. 2021;12:204062232111056712.
- Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *Eur Respir Rev*. 2018;27(147):170077.
- Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med*. 2006;173(12):1390-1413.
- Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. *Lancet*. 1996;348(9035):1115-1119.
- McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2015;(2)CD003793.
- Migliori GB, Marx FM, Ambrosino N, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. *Int J Tuberc Lung Dis*. 2021;25(10):797-813. <https://doi.org/10.5588/ijtld.21.0425>
- Gimigliano F, Negrini S. The World Health Organization "Rehabilitation 2030: a call for action." *Eur J Phys Rehabil Med*. 2017;53(2):155-168.
- Alene KA, Hertzog L, Gilmour B, Clements AC, Murray MB. Interventions to prevent post-tuberculosis sequelae: a systematic review and meta-analysis. *EClinicalMedicine*. 2024;70:102511.
- Habib GMM, Rabinovich R, Divgi K, et al. Systematic review of clinical effectiveness, components, and delivery of pulmonary rehabilitation in low-resource settings. *NPJ Prim Care Respir Med*. 2020;30(1):52.
- Sealed Envelope. *Randomization and Online Databases for Clinical Trials*. Sealed Envelope website. Accessed March 10, 2026. <https://www.sealedenvelope.com/>
- Katagira W, Orme MW, Jones AV, et al. Study protocol for a randomised controlled trial assessing the impact of pulmonary rehabilitation on maximal exercise capacity for adults living with post-TB lung disease: Global RECHARGE Uganda. *BMJ Open*. 2021;11(8):e047641.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update: an official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med*. 2019;200(8):e70-e88.
- Global Initiative for Asthma (GINA). *Global Initiative for Asthma 2020 Report*. 2020. Global Initiative for Asthma website. Accessed March 9, 2026. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_final_wms.pdf
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report*. 2020. Global Initiative for Chronic Obstructive Lung Disease website. Accessed March 9, 2026. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
- Evans RA, Singh SJ. Minimum important difference of the Incremental Shuttle Walk Test distance in patients with COPD. *Thorax*. 2019;74(10):994. <https://doi.org/10.1136/thoraxjnl-2018-212725>
- Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J*. 2014;44(6):1428-1446.
- Orme MW, Free RC, Manise A, et al. Global RECHARGE: establishing a standard international data set for pulmonary rehabilitation in low- and middle-income countries. *J Glob Health*. 2020;10(2):020316.
- Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. *Thorax*. 2014;69(9):793-798.
- Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. *Lancet Respir Med*. 2014;2(3):195-203.
- Smid DE, Franssen FM, Houben-Wilke S, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary

- 1211 rehabilitation: a prospective analysis. *J Am Med Dir Assoc.* 2017;18(1):53-58. 1248
- 1212 28. Wynne S, Patel S, Barker RE, et al. The 1249
- 1213 Hospital Anxiety and Depression Scale 1250
- 1214 (HADS) in bronchiectasis: response to 1251
- 1215 pulmonary rehabilitation (PR) and 1252
- 1216 minimum clinically important difference 1253
- 1217 (MCID). *Chron Respir Dis.* 2020;17: 1254
- 1218 1479973120933292. 1255
- 1219 29. Löwe B, Unützer J, Callahan CM, 1256
- 1220 Perkins AJ, Kroenke K. Monitoring 1257
- 1221 depression treatment outcomes with the 1258
- 1222 Patient Health Questionnaire-9. *Med 1259*
- 1223 Care. 2004;42(12):1194-1201. 1260
- 1224 30. Zatloukal J, Ward S, Houchen-Wolloff L, 1261
- 1225 Harvey-Dunstan T, Singh S. The minimal 1262
- 1226 important difference for the Endurance 1263
- 1227 Shuttle Walk Test in individuals with 1264
- 1228 chronic obstructive pulmonary disease 1265
- 1229 following a course of pulmonary 1266
- 1230 rehabilitation. *Chron Respir Dis.* 2019;16: 1267
- 1231 1479973119853828. 1268
- 1232 31. Jones SE, Kon SS, Canavan JL, et al. The 1269
- 1233 five-repetition sit-to-stand test as a 1270
- 1234 functional outcome measure in COPD. 1271
- 1235 *Thorax.* 2013;68(11):1015-1020. 1272
- 1236 32. De Torres JP, Pinto-Plata V, Ingenito E, 1273
- 1237 et al. Power of outcome measurements to 1274
- 1238 detect clinically significant changes in 1275
- 1239 pulmonary rehabilitation of patients with 1276
- 1240 COPD. *Chest.* 2002;121(4):1092-1098. 1277
- 1241 33. Crisafulli E, Clini EM. Measures of 1278
- 1242 dyspnea in pulmonary rehabilitation. 1279
- 1243 *Multidiscip Respir Med.* 2010;5(3): 1280
- 1244 202-210. 1281
- 1245 34. Zanini A, Aiello M, Adamo D, et al. 1282
- 1246 Estimation of minimal clinically 1283
- 1247 important difference in EQ-5D visual 1284
35. Van Hout B, Janssen M, Feng Y-S, et al. 1285
- Interim scoring for the EQ-5D-5L: 1286
- mapping the EQ-5D-5L to EQ-5D-3L value 1287
- sets. *Value Health.* 2012;15(5):708-715. 1288
36. European Quality of Life (EuroQol). *Value 1289*
- Sets for Scoring EQ-5D [country-specific 1290
- index value calculator]. 2024. European 1291
- Quality of Life website. Accessed August 6, 1292
2024. [https://euroqol.org/information- 1293](https://euroqol.org/information-and-support/resources/value-sets/)
- [and-support/resources/value-sets/ 1294](https://euroqol.org/information-and-support/resources/value-sets/)
37. OANDA. *Currency Converter.* OANDA 1295
- website. 2024. Accessed October 31, 2024. 1296
- [https://www.oanda.com/currency- 1297](https://www.oanda.com/currency-converter/en)
- [converter/en 1298](https://www.oanda.com/currency-converter/en)
38. List JA, Shaikh AM, Xu Y. Multiple 1299
- hypothesis testing in experimental 1300
- economics. *Exp Econ.* 2019;22:773-793. 1301
39. ISRCTN Clinical Study Registry. Does 1302
- pulmonary rehabilitation improve the 1303
- health of post tuberculosis patients living 1304
- in Uganda? ISRCTN18256843. 2019. 1305
- Updated 2023. [https://www.isrctn.com/ 1306](https://www.isrctn.com/ISRCTN18256843)
- [ISRCTN18256843 1307](https://www.isrctn.com/ISRCTN18256843)
40. Jones R, Kirenga BJ, Katagira W, et al. 1308
- A pre-post intervention study of 1309
- pulmonary rehabilitation for adults with 1310
- post-tuberculosis lung disease in Uganda. 1311
- Int J Chron Obstruct Pulm Dis.* 2017;12: 1312
- 3533-3539. 1313
41. Orooj M, Pant A, Mujaddadi A, Jain M, 1314
- Ahmed I. Short-term pulmonary 1315
- rehabilitation among post-pulmonary 1316
- tuberculosis patients during coronavirus 1317
- disease 2019 pandemic. *Thorac Res Pract.* 1318
- 2023;24(3):131-136. 1319
42. Singh SK, Naaraayan A, Acharya P, 1320
- Menon B, Bansal V, Jesmajian S. 1321
- Pulmonary rehabilitation in patients with 1322
- chronic lung impairment from 1323
- pulmonary tuberculosis. *Cureus.* 2018;10 1324
- (11):e3664. 1325
43. Ando M, Mori A, Esaki H, et al. The 1326
- effect of pulmonary rehabilitation in 1327
- patients with post-tuberculosis lung 1328
- disorder. *Chest.* 2003;123(6):1988-1995. 1329
44. Silva DR, Mello FCdQ, Galvão TS, et al. 1330
- Pulmonary rehabilitation in patients with 1331
- post-tuberculosis lung disease: a 1332
- prospective multicentre study [article in 1333
- English, Spanish]. *Arch Bronconeumol.* 1334
- 2025;61(10):603-609. 1335
45. Nolan CM, Delogu V, Maddocks M, et al. 1336
- Validity, responsiveness and minimum 1337
- clinically important difference of the 1338
- incremental shuttle walk in idiopathic 1339
- pulmonary fibrosis: a prospective study. 1340
- Thorax.* 2018;73(7):680-682. 1341
46. Lee A, Hill CJ, Cecins N, et al. Minimal 1342
- important difference in field walking tests 1343
- in non-cystic fibrosis bronchiectasis 1344
- following exercise training. *Respir Med.* 1345
- 2014;108(9):1303-1309. 1346
47. Franssen FM, Rochester CL. 1347
- Comorbidities in patients with COPD and 1348
- pulmonary rehabilitation: do they matter? 1349
- Eur Respir Rev.* 2014;23(131):131-141. 1350
48. Singh SJ, Puhon MA, Andrianopoulos V, 1351
- et al. An official systematic review of the 1352
- European Respiratory Society/American 1353
- Thoracic Society: measurement properties 1354
- of field walking tests in chronic 1355
- respiratory disease. *Eur Respir J.* 2014;44 1356
- (6):1447-1478. 1357
49. Yohannes AM, Murri MB, Hanania NA, 1358
- et al. Depressive and anxiety symptoms in 1359
- patients with COPD: a network analysis. 1360
- Respir Med.* 2022;198:106865. 1361
50. Devlin N, Parkin D. Does NICE have a 1362
- cost-effectiveness threshold and what 1363
- other factors influence its decisions? A 1364
- binary choice analysis. *Health Econ.* 1365
- 2004;13(5):437-452. 1366